Insufficiently Defined Genetic Background Confounds Phenotypes in Transgenic Studies As Exemplified by Malaria Infection in Tlr9 Knockout Mice

Nathalie Geurts1, Erik Martens1, Sebastien Verhenne1*, Natacha Lays1, Greet Thijs1, Stefan Magez2, Bénédicte Cauwe1, Sandra Li1, Hubertine Heremans1, Ghislain Opdenakker1, Philippe E. Van den Steen1*

1 Laboratory of Immunobiology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium, 2 Laboratory for Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium

Abstract

The use of genetically modified mice, i.e. transgenic as well as gene knockout (KO) and knock-in mice, has become an established tool to study gene function in many animal models for human diseases. However, a gene functions in a particular genomic context. This implies the importance of a well-defined homogenous genetic background for the analysis and interpretation of phenotypes associated with genetic mutations. By studying a Plasmodium chabaudi chabaudi AS (PcAS) malaria infection in mice bearing a TLR9 null mutation, we found an increased susceptibility to infection, i.e. higher parasitemia levels and increased mortality. However, this was not triggered by the deficient TLR9 gene itself. Instead, this disease phenotype was dependent on the heterogeneous genetic background of the mice, which appeared insufficiently defined as determined by single nucleotide polymorphism (SNP) analysis. Hence, it is of critical importance to study gene KO phenotypes on a homogenous genetic background identical to that of their wild type (WT) control counterparts. In particular, to avoid problems related to an insufficiently defined genetic background, we advocate that for each study involving genetically modified mice, at least a detailed description of the origin and genetic background of both the WT control and the altered strain of mice is essential.

Introduction

The major histocompatibility complex (MHC) on human chromosome 6 covers a large genomic region with a central role in determining the degree of disease susceptibility. In this locus, small gene polymorphisms, typically located in alleles in charge of protein processing and presentation as well as immune regulation, are associated with several human autoimmune diseases, e.g. multiple sclerosis, type 1 diabetes and rheumatoid arthritis, but also with infectious diseases, e.g. malaria [1–6]. Aside the MHC having a major impact on immune phenotypes, many genes outside this susceptibility locus contribute to immunomodulation. This is increasingly recognized by genome-wide association studies (GWAS) in which genes encoding cytokines, cytokine receptors and pattern recognition receptors (PRRs), e.g. Toll-like receptors (TLRs), RIG-I-like receptors (RLRs), Nod-like receptors (NLRs) are identified to play small but definite effects that may synergize [7,8]. In addition, single nucleotide polymorphisms (SNPs) in TLRs are found to correlate with susceptibility to infectious diseases [9]. For instance, polymorphisms in TLR1, TLR4 and TLR9 are associated with an aggravated clinical status of malaria during pregnancy [10,11]. Polymorphisms in TLR4 are also reported to play a role in controlling the parasitemia level in malaria [12]. Furthermore, in malaria, alleles associated with sickle-cell anemia, thalassemias, and glucose-6-phosphate dehydrogenase deficiency confer protective effects, whereas polymorphisms in the TNF-α gene have been linked to increased risk of cerebral malaria (CM) [13]. Hence, complex host genetics, in addition to environmental factors, are invoked in defining susceptibility or resistance against several diseases.

In malaria research, many groups attempted to examine the role of TLRs by using TLR−/− mice. Both in human and experimental malaria, enhanced TLR activation is suggested to prime proinflammatory cytokine responses (IL-12, IFN-γ, TNF-α), which in turn can favor host hyperresponsiveness to TLR agonists during acute malaria. Subsequently, excessive inflammation might contribute to malaria pathology, such as fever, CM and anemia [14,15]. Therapeutical treatment with TLR antagonists was found to diminish TLR activation and to prevent the development of experimental cerebral malaria (ECM) [16]. Tolerance to TLR signaling, however, was observed in a murine malaria model at later stages of infection and was paralleled by an anti-inflamma-
The fact that the phenotype of a single gene mutation is frequently modulated by a large number of background genes has been illustrated by Griffith et al., who have studied the role of TLR signaling in the development of ECM [18]. It was shown that knocking out MyD88 or TLR9 in the CM-susceptible Th2-permissive C57Bl/6 background turns out into a resistant phenotype, whereas in CM-resistant Th2-permissive Balb/c mice, interruption of the TLR pathway by deleting MyD88 results in development of CM and increased mortality. Thus, two congenic strains carrying the same null mutation can have a divergent phenotype dependent on their genetic background. This is, however, not unique to malaria-related phenotypes [19–21]. Coban et al. also revealed that TLR2-, TLR9- and MyD88-dependent signaling is essential in murine CM on a C57Bl/6 background [22]. However, controversies on the contribution of the TLR cascade to the development of experimental CM pathogenesis exist as several studies ascertain that murine CM is independent of TLR signaling [23,24]. In addition, the route of infection also appears to influence the effect of the TLR pathway on CM [25].

*Plasmodium spp.* have been shown to contain ligands for TLRs. Besides TLR2 that recognizes malarial glycosylphosphatidylinositol [26], TLR9 gained attention since hemozoin or malaria pigment, which is a crystalline detoxification product of heme formed in the food vacuole of parasites during hemoglobin digestion, has been described as a ligand of TLR9 able to induce immune activation [27,28]. However, it is still a matter of debate whether hemozoin itself binds this receptor, whether malaria pigment carries plasmoidal DNA to TLR9 or whether the TLR9 ligand is a histone-DNA complex [29–32]. Recently, it was discovered that several hemozoin effects are dependent on its stable interaction with host fibrinogen and the activation of receptors TLR4/integrin by this complex [33].

In this study, we attempted to further examine the role of TLR9 in a *Plasmodium chabaudi chabaudi* (PAS) infection model. First, we used a common practice strategy, by studying and comparing commercial wild type mice from Janvier (WT[Jv]) with the TLR9+/− mice that we originally received (OR). Subsequently, the validity of this strategy was investigated by performing an additional backcross and by in-depth investigation of the genetic background of these mice. Our data demonstrate that phenotypic differences observed between mutant and control mice can simply result from the effect of background genes and this might lead to misinterpretation of results.

**Results**

**Infection-induced phenotypic differences between WT[Jv] and TLR9+/−(OR) are lost after one additional backcross generation**

The infection of C57Bl/6 WT mice with PAS is characterized by an acute primary peak of parasitemia around day 9–10, followed by a chronic phase marked by one or two small recrudescences around day 30 post infection (pi). Finally, the parasite is cleared and mice survive the infection [34]. Since TLR9 is a crucial component connecting innate and adaptive immunity, it was interesting to investigate the role of TLR9 in protective immunity against blood-stage PAS. The TLR9 genotype of each mouse was confirmed by PCR (Figure S1). In first instance, we compared the course of PAS infection in the originally received B6.TLR9+/−(OR) mice and commercial inbred B6.WT[Jv] mice and observed a phenotype in parasitemia. Primary parasitemia peaked between 7 and 12 days pi and peak values of individual mice were significantly higher in B6.TLR9+/−(OR) mice compared to B6.WT[Jv] mice (Figures 1A–B; p<0.01). During the chronic stage of infection between day 20 and day 44 pi, B6.TLR9+/−(OR) mice suffered from 10-fold higher levels of recrudescent parasitemia (median = 10.1%) compared to the B6.WT[Jv] controls, which had only small recrudescences (median = 0.09%) (Figure 1C; p<0.01). Moreover, infected B6.TLR9+/−(OR) mice became considerably more anemic (Figure S2; p<0.001) and limited but significant mortality was observed in large cohorts among these TLR9-deficient mice, whereas B6.WT[Jv] mice were fully resistant to PAS infection (Figure 1D; p<0.01 by Log-rank (Mantel Cox) test). Hence, although discrepant from other published data [15,33–38], the B6.TLR9+/−(OR) mice were less well protected against acute and chronic parasitemia.

As antibody-dependent immunity is considered essential during blood-stage malaria infection, particularly for the resolution of the chronic stage of infection [39–42], we tried to explain antiparasite immunity with known TLR9 effects on antibody responses [43,44] (Figure S3). Our data suggested that IgM, IgG2b and IgG2c antibodies might play a role in the protective immunity to control acute and chronic stage PAS infection, whereas IgG1 was inversely correlated with parasite control. Serum transfer experiments were performed and significant antiparasite activity was observed only when immune sera were derived from commercial B6.WT[Jv] mice and not from B6.TLR9+/−(OR) mice (Figure S4). The Th2-skewed antibody profile in B6.TLR9+/−(OR) mice together with the inability of B6.TLR9+/−(OR) immune sera to affect primary parasitemia levels caused the impression that TLR9 liganding assists in the generation of a protective antibody profile essential for the acquisition of anti-malaria immunity. However, this was in contradiction to the results published by Seixas et al., who showed that both parasitemia control and antibody production were not affected by a TLR9 deletion [35].

To determine whether the observed difference in susceptibility to PAS infection between B6.WT[Jv] and B6.TLR9+/−(OR) mice was due to the inactivation of the TLR9 gene or to genetic and phenotypic line differences unrelated to the targeted mutation, B6.WT[Jv] and B6.TLR9+/−(OR) mice were crossed and heterozygous progeny were mated to obtain matched B6.WT and B6.TLR9+/− lines. These additionally backcrossed B6.TLR9+/−[BC] mice and their B6.WT[BC] controls were infected with 10^4 PAS pRBCs and the course of parasitemia was monitored. However, in contrast to our observations with the B6.TLR9+/−(OR) mice (Figures 1A–C), no significant differences in the course of parasitemia between the B6.WT[BC] and B6.TLR9+/−[BC] mice were noticed (Figures 1E–G). Indeed, acute as well as recrudescent peak parasitemia values between both control and mutant lines were comparable in this experimental setup (Figures 1F–G). In addition, all B6.TLR9+/−[BC] mice survived the infection (Figure 1H), whereas some mortality was observed in the B6.TLR9+/−(OR) mice used in the initial experimental setup (Figure 1D).

These data, however, reinforce the published ones [15,33–38] and called for a reconsideration of the genetic background. SNPs, the single most abundant class of genetic variation in mammals, have become the markers of choice to distinguish inbred mouse strains on a genetic basis.

Extensive SNP genotyping was performed by Charles River as detailed in the Materials and Methods section. Fourteen samples were tested: B6.WT [Jv, samples 1–4], B6.TLR9+/−(OR, samples 5–8), B6.WT[BC, samples 9–11] and B6.TLR9+/−[BC, samples
Figure 1. One additional backcross generation (B6.TLR9^+/+ (BC) and B6.WT(BC)) abolishes the phenotypic differences in the course of infection between B6.WT(Jv) and B6.TLR9^+/+ (OR) mice. As detailed in materials and methods, B6.WT(Jv) mice were intercrossed with B6.TLR9^+/+ (OR) mice and heterozygotes (F1) were mated to obtain matched backcrossed B6.WT(BC) and B6.TLR9^+/+ (BC) mice. The offspring were used for experiments. B6.WT(Jv) (black circles), B6.TLR9^+/+ (OR) (grey squares), B6.WT(BC) (open circles) and B6.TLR9^+/+ (BC) (open squares) mice were infected ip with 10^6 PcAS pRBCs. (A,E) The course of parasitemia was monitored for 44 days by microscopic examination of thin Giemsa-stained
blood smears. Since not all mice reached their maximum peak parasitemia on the same day, the highest parasitemia of each individual mouse between day 7 and 12 was selected as peak parasitemia and indicated as a single dot. The horizontal lines indicate the group medians. Since the timing of the recrudescences varied significantly between 20 and 44 days pi, the peak parasitemia values during recrudescences between day 20 and day 44 pi are shown and represented as single dots. The horizontal lines indicate the group medians. Survival was monitored until 44 days pi in the four different groups. Data are representative of more than three independent experiments with at least five mice per group in each experiment. Data are a compilation of several experiments with at least five mice per group. Data are a compilation of two independent experiments with at least seven mice per group at each time point. ns, not significant. The numbers of mice (n) in each group are depicted in the graph legend. **, p<0.01; ***, p<0.001.

doi:10.1371/journal.pone.0027131.g001

12–14 (Table S1). In addition, the TLR9 genotype of each mouse was confirmed by PCR (Figure S1). Although we started our experiments with the confirmation that the B6.TLR9-/- (OR) mice were at least 10-fold backcrossed to an inbred C57Bl/6 background, the SNP analysis ascertained significant genetic background differences in the B6.WT(Jv) versus B6.TLR9-/- (OR) mice. In essence, the B6.TLR9-/- (OR) mice were definitely not congenic to C57Bl/6 as these animals still had large regions of 129 DNA unlinked to the TLR9 gene. This 129 DNA originates from the 129-derived embryonic stem (ES) cells carrying the targeted mutation. When considering only those SNPs that differentiate between C57Bl/6 and 129, the analysis revealed an average of 69% C57Bl/6 DNA in the B6.TLR9-/- (OR) mice (Figure 2; Table S1, samples 5–8). This indicates that only a maximum of two backcross generations had occurred. According to classic genetics, however, the average percentage of the genetic material after backcrossing a 129 chimera with a C57Bl/6 mouse for two generations is expected to be 75%. It might be possible that continuous long-term inbreeding of the ‘two generations backcrossed TLR9-/- (OR) mice’ had favored a positive selection for 129 genes, thereby increasing the percentage of 129 DNA at the expense of C57Bl/6 DNA. The additional backcross that we performed to produce mixed control and mutant lines increased the degree of C57Bl/6 DNA in the new B6.TLR9-/- (BC) mice by approximately 15% (Figure 2; Table S1, samples 12–14), but also ‘generated’ the new B6.WT (BC) mice with a similar level of non C57Bl/6 DNA including 129 DNA (Figure 2; Table S1, samples 9–11).

Discussion

Genetic components determining host susceptibility to malaria are complex, both in human and in mice [45]. Considerable efforts have been made to identify the genes responsible for the development of the disease [13]. In human malaria, for example, control of parasitemia levels was found to be linked to a locus on chromosome 5q31-q33 [46].

Approximately 99% of human genes have mouse homologs and the gene order is highly conserved. Hence, the mouse has served as an appropriate experimental model that allowed to dissect complex genetic traits and to decipher immunopathological pathways of several complex human diseases. Inbred mouse strains are generated by at least 20 sequential generations of sibling mating, which drives heterozygous loci to homozygosity and increases the genetic uniformity of the line. After 20 generations of inbreeding, on average 98.6% of the genome should be homozygous. This enables researchers to conduct relevant experiments [47]. Several studies, however, highlight the importance of the genetic background of the mouse strain used to mimic and investigate human disease phenotypes. This is illustrated by inbred mouse models of malaria infection, in which the outcome is dependent upon the genetic background of the host. Indeed, C57Bl/6 mice are resistant to infection with P.e., whereas A/J mice succumb to infection due to uncontrolled parasitemia and severe anemia accompanied by suppressed erythropoiesis [40,48–50]. Quantitative trait locus (QTL) mapping studies in recombinant congenic mouse strains have identified several Chabaudi resistance (Char) loci on various chromosomes important in controlling susceptibility to P.e. infection, and hence, underlining the complexity and multicentricity in parasite control [51–54].

In the last decade, the use of mice carrying engineered genetic modifications has revolutionized the study of gene function. However, these new techniques also have their drawbacks and special care should be taken when the target genes are involved in a complex network of interacting genes and biochemical processes, which is the case for most immunological events. Indeed, the phenotype of a mutation is often tuned by a particular genomic context in which flanking genes as well as the genetic background contribute to the induced mutation (reviewed by Sigmund et al. [19]). As an example, outside of malaria research, an epidermal growth factor null mutation on a CF-1 background results in early embryonic death, whereas homozygous mutants on a 129/Sv background die at mid gestation. On a CD-1 background, the mutants survive for 3 weeks [20]. Hence, genes should not be studied alone but have to be seen in an epistatic multigenic network. It is extremely important to use congenic strains when evaluating phenotypes resulting from gene manipulation [19]. Congenic strains are defined as two inbred strains which are genetically identical, except for the targeted gene and its flanking region [53,56]. Eliminating the confounding effects of background genes will improve the understanding of gene function. Most commonly used ES cell lines for gene targeting are derived from strain 129. Using traditional backcrossing methods, the 129 genome is progressively diluted. At least 7 generations of backcrossing to a maintenance inbred strain (usually C57Bl/6) are required to establish congenic lines with more than 99% genetic homogeneity. However, the region flanking the mutated gene still contains 129 DNA. It is recommended to characterize knockout phenotypes on several different and clearly defined
Genetic Context Confounds Malaria TLR9 Phenotype

backgrounds. More ideally, besides the conditional knockout models, the use of co-isogenic lines, defined as two inbred strains that carry different alleles of only one gene but which are otherwise genetically identical, will overcome the flanking gene problem (use of ES cells from desired strain) [19,57–61].

An additional hurdle is that, although inbred strains are forced to homozygosity and genetic uniformity, minor variations within an inbred strain have been found. Moreover, when inbred strain colonies are separated and raised in a different environment or at another laboratory, substantial strain differences may occur. The use of different substrains from the same inbred strain can hamper the reproducibility and interpretation of experimental results. Genetic variation arises by accidental genetic contamination due to errors in animal management, or by genetic drift. Genetic drift favors fixation of new mutations or the elimination of residual heterozygosity and leads to changes in inbred strains over time or between inbred lines that were physically separated (i.e. substrains). Commercial breeders have specific breeding programs to slow down genetic drift, e.g. the Genetic Stability Program (GSP) of The Jackson Laboratory [62–64]. It is essential to acknowledge the phenomena of spontaneous mutations and genetic drift regarding the use of WT mice from a commercial breeder or other sources as ‘controls’ when designing studies with genetically engineered mice. A solution may be to intercross both inbred WT control mice with KO mice and use enough WT and KO progeny from F2 for experimental setup. Applying this strategy will scramble the genetic background of both mouse lines and even out a large part of small line variations.

The data presented in this study highlight the importance of a well-defined homogenous genetic background - which should be as similar as possible between the control and the mutant line - in the analysis of the effect of a TLR9 deletion on the parasitemia course during a P. chabaudi infection. In our first experimental setup, an increased susceptibility against P. chabaudi infection was observed in mice lacking TLR9, which were originally received as being at increased susceptibility against P. chabaudi during a assortment of chromosomes and chromosomal crossovers, some of random genetic recombination in meiosis, e.g. by independent lost. Reassessment of the genetic identity of the original additional generation, the TLR9 KO-associated phenotype was heterogeneous genetic background composed of C57Bl/6 DNA observed increased susceptibility phenotype might be due to some 129 DNA at the expense of C57Bl/6 genetic material. B6.WT(BC) mice. Indeed, these B6.WT(BC) mice have gained similar hypothesis can also be applied to the observed increased susceptibility/resistance to high parasitemia (reviewed in [49]). Several loci on several chromosomes are associated with different susceptibilities to P. chabaudi have revealed that several loci on many chromosomes are associated with susceptibility/resistance to high parasitemia (reviewed in [49]). A similar hypothesis can also be applied to the observed increased recrudescence parasitemia values observed in some of the new B6.WT(BC) mice. Indeed, these B6.WT(BC) mice have gained some 129 DNA at the expense of C57Bl/6 genetic material. Rather than being induced simply by the TLR9 null mutation, the observed increased susceptibility phenotype might be due primarily to ‘contaminating’ 129 DNA. This theory is indeed supported by the fact that the 129 mouse strain is also susceptible for P. chabaudi AS infection [49]. A third possibility might be that the enhanced susceptibility phenotype is induced by epistatic interactions of uncharacterized background genes, originating from DNA of 129 and C57Bl/6 mouse strains. An illustration of a phenotype induced by the combined effect of both 129 and C57Bl/6 genetic material is provided by Bygrave et al. [65]. These authors have shown that, in the absence of any gene-targeted mutations, the interplay between loci of 129 and C57Bl/6 mice was sufficient to cause humoral autoimmunity. Hence, the additional intercross between B6.WT(Jv) and B6.TLR9−/−(OR) mice has shuffled their genetic background and evened out the phenotypic line differences which were probably due to 129 DNA and unrelated to the TLR9 deletion. In accordance herewith, Sexias et al. did also not observe any effect of TLR9 deficiency on the course of parasitemia and antibody profiles during a P. chabaudi AS infection [35].

Guided by the results presented in this study and in addition to several other reports that stress complications in the experimental setup of knockout studies [39–61], it has to be acknowledged that the poor description of the mouse genetic constitution in many published reports is in sharp contradiction with the rules of classical genetics. Table 1 lists the experimental setup and results of 5 studies on the effect of a TLR9 deletion in a P. chabaudi AS infection. In addition, 13 studies on the role of TLR9 in other malaria models are included for further comparison. From this, it is clear that often insufficient information on the genetic setup of the used KO and control WT mice is provided. This is in part due to the free circulation of many KO mouse strains between many laboratories worldwide, sometimes resulting in the loss of the correct information on the genetic background. In addition, the WT mice are often obtained from a commercial breeder, which raises concerns about the use of these mice as controls. Indeed, even if the KO strain is sufficiently backcrossed into an inbred line, it is important to use non-transgenic control mice derived from the same inbred line, as this will minimize strain differences due to genetic drift. Alternatively, intercrossing of the control WT mice and the KO mice is convincing as a final confirmation of the obtained results, if in vivo neutralization of the target protein is practically unachievable. More advanced approaches to study gene function are the ‘conditional knockout’ models or the use of ES cells from the required strain [59]. The reason behind the discrepant results summarized in Table 1 concerning the role of TLR9 in malaria pathogenesis might be due to the distinct experimental designs of the mouse studies by different research groups. This problem of genetic background effects may not be limited to the role of TLR9 in P. chabaudi AS infections, but may also be relevant for other studies with other mouse models, even not related to malaria. Furthermore, besides host genetics, other factors may be invoked in determining susceptibility to P. chabaudi AS and other malaria strains, i.e. parasite substrains and genetics, breeding and housing conditions, intestinal flora, food, sex, age and also the source and route of infection [25, 66–69].

As a conclusion, in phenotype studies of genetically modified animals, a significant impact on the phenotype may come from the culmination of small effects by many genes that may be different between wild type and modified animals. These differences may be minimized by a sufficient number of backcrosses. Ideally, gene function has to be studied between congenic or even co-isogenic strains. For the sake of reproducibility, all reports concerning genetic experiments must include detailed information on the origin and the genetic background of the studied animals.
### Table 1. Overview of the genetic background of TLR9−/− mice in experimental malaria infections.

| CONTROL STRAIN | KNOCKOUT STRAIN | N° of backcross generations to the WT background | TLR9 knockout phenotype | Ref. |
|----------------|-----------------|-----------------------------------------------|------------------------|------|
| **Plasmodium chabaudi AS** | | | | |
| B6.WT(?) + PbAS | undefined | B6.TLR9−/−(?) + PbAS | undefined | no difference in parasitemia, in body weight and in temperature, ↓ production of IFN-γ by splenocytes on day 8 pi | [36] |
| B6.WT (local breeding facility) + PbAS | undefined (*pure local C57Bl/6 line) | B6.TLR9−/− (Prof. Akira, Japan) + PbAS | undefined (*at least 8-9× on local inbred line) | no difference in parasitemia, no difference in the alterations in splenic microarchitecture | [37] |
| B6.WT(JL) (DCs) + PbAS | according to commercial breeder strategy [75] | B6.TLR9−/− (Prof. Akira, Japan) + PbAS | at least 8× | no difference in parasitemia, ↓ TLR upregulation, ↓ production of IFN-γ/IL-12 by splenocytes/ DCs, ↑ resistance against LPS-induced mortality | [15] |
| B6.WT (?; *local breeding facility) (pDCs) + PbAS | undefined (*pure local C57Bl/6 line) | B6.TLR9−/− (Prof. Akira, Japan) + PbAS | 10× | ↓ IFN-γ production in co-culture of pDC+iRBC, ↓ IFN-γ mRNA in pDC on day 3 pi, no difference in parasitemia, body weight and temperature | [38] |
| B6.WT (local breeding facility) (DCs) + PbANKA or PbANKA | undefined | B6.TLR9−/− (Prof. Akira, Japan) + PbANKA or PbAS | undefined | ↓ DC activation by parasites, no nuclear translocation of NF-kB in DCs, no difference in parasitemia (PcAS), ↓ in vivo activation of splenic DCs, ↑ IgM on day 10 pi (PcAS) | [35] |
| **Plasmodium berghei ANKA** | | | | |
| B6.WT(?) + PbANKA | undefined | B6.TLR9−/− (Prof. Akira, Japan) + PbANKA | at least 10× | ↓ macrophage response to pRBCs, no difference in parasitemia, in lung and hepatic pathology, in CM development and in survival | [23] |
| B6.WT(JL) + PbANKA | according to commercial breeder strategy [75] | B6.TLR9−/−(?) + PbANKA | at least 7× | no difference in parasitemia, ↑ survival, ↓ CM | [18] |
| B6.WT (CLEA, Japan) + PbANKA | according to commercial breeder strategy [76] | B6.TLR9−/− (Prof. Akira, Japan) + PbANKA | at least 8× | no difference in parasitemia, ↑ survival, ↓ CM | [22] |
| B6.WT (?; *local breeding facility) + PbANKA | undefined (*pure C57Bl/6 line from local breeding facility) | TL2/4/9−/− (Kirschning, Munich) + PbANKA | mixed (129SVxC57Bl/6) | no difference in parasitemia, CM development and survival | [24] |
| **Plasmodium yoelii** | | | | |
| B6.WT (Kyudo, Japan) + P. yoelii | undefined | B6.TLR9−/− (Prof. Akira, Japan) + P. yoelii | at least 15× | partial resistance to lethal infection (parasitemia, survival), ↓ activation of Tregs by DCs, ↑ activation of CD4+ T cells | [68] |
| Balb/c.WT (CLEA Japan) + immunization with baculovirus-based PyMSP119 + P. yoelii 17XL | according to commercial breeder strategy [76] | Balb/c.TLR9−/− (Prof. Akira, Japan) + immunization with baculovirus-based PyMSP119 + P. yoelii 17XL | undefined | vaccine induced protection abolished, ↑ Th2 immune responses | [77] |
| **Parasite components** | | | | |
| B6.WT (CLEA Japan): DCs + schizont extracts | according to commercial breeder strategy [76] | B6.TLR9−/− (Prof. Akira, Japan) + Schizont extract | 8× | ↓ schizont-induced DC activation | [27] |
| B6.WT (?; *CLEA Japan) (DCs) + n/sHz | undefined (*according to commercial breeder strategy [76]) | B6.TLR9−/− (Prof. Akira, Japan) + DCs + n/sHz | undefined (*at least 8×) | ↓ innate immune activation by n/sHz | [28] |
| B6.WT(JL): DCs + n/sHz | according to commercial breeder strategy [75] | B6.TLR9−/− (Prof. Akira, Japan) + DCs + n/sHz | more than 10× (genetic background analyzed by microsatellite analysis (Charles River Laboratories)) | ↓ innate immune activation by plasmodial DNA on Hz | [31] |
| B6.WT(JL) (macrophages) + sHz | according to commercial breeder strategy [72] | B6.TLR9−/− (Prof. Akira, Japan) + Macrophages + sHz | 9× | no difference in inflammatory response to sHz | [78] |
Mice were infected intraperitoneally (ip) with blood containing 10^4 Plasmodium chabaudi chabaudi infected red blood cells (pRBCs) (a kind gift of the late Prof. Dr. D. Walliker, University of Edinburgh, Scotland, U.K.). 10^4 pRBCs as infectious dose was previously used by our laboratory and also by others [71–74]. Mice received high energy food and drinking water was supplied with para-amino benzoic acid (PABA) to improve in vivo parasite growth. Parasitemia of individual mice was monitored microscopically on Giemsa-stained blood smears.

### Background strain characterization testing via Single Nucleotide Polymorphisms (SNP) markers

Background strain characterization was performed at Charles River (Charles River Genetic Testing Services, Troy, NY, USA). Mouse tissue samples were tested with a background strain characterization panel to evaluate strain line purity. The panel consisted of 384 SNP markers. The SNP markers were spread across the 19 mouse autosomes and the X chromosome at about 7 Mbp intervals and were polymorphic between various strains of mice. In particular, 199 SNPs were polymorphic between C57Bl/6 and 129. An array of inbred and hybrid controls were also analyzed along with the samples. From 4 B6.WT(Jv), 4 B6.TLR9⁻/⁻(OR), 3 B6.WT(BC) and 3 B6.TLR9⁻/⁻(BC) mice, tail DNA was prepared using the Nucleospin Tissue Kit (Clontech Laboratories, Mountain View, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray chips (Applied Biosystems, Foster City, CA, USA). Subsequently, the DNA was loaded into OpenArray ch
Once the array had been cycled, VIC and FAM fluorescence (corresponding to the two possible SNP alleles) were quantified by analyzing the array in an OpenArray Imager. Fluorescence data were analyzed using the OpenArray SNP Genotyping Analysis software (Applied Biosystems). Genotyping data were exported to Microsoft Excel, sorted to place the markers in chromosomal order, and pasted into a strain-specific scoring template to convert the alleles present in each sample to numerical values. Markers homozygous for the expected allele in the background to be quantified were scored as “1”. Markers heterozygous for the expected allele and another allele were scored as “0.5”. Markers homozygous for another allele were scored as “0”. The score for each marker was averaged to calculate the percent of the strain of interest in the background.

Statistical analysis

Data are presented as scatter dot plots with the line indicating the median. Using the GraphPad Prism 5 software (GraphPad Software, San Diego, CA, USA), the nonparametric Mann-Whitney U-test was applied to determine the statistical significance of the observed differences between two groups. Survival was analyzed by the Log-rank (Mantel Cox) Test. Differences were considered statistically significant when \( p < 0.05 \) (two-tailed).

Supporting Information

Text S1 Online supporting results and supporting materials and methods. Discussion on the results of figure S3 (antibody levels) and figure S4 (antibody transfer experiment). Detailed information on the supporting materials and methods. (XLSX)

Figure S1 Genotype confirmation by PCR followed by DNA separation and visualization on an agarose FlashGel DNA cassette. Genomic DNA was extracted from mouse tail samples as detailed in the supporting Text S1. The TLR9 knockout (upper gel) versus WT (lower gel) genotype was detected by PCR and the amplified products were separated and visualized on a 1.2% agarose FlashGel DNA cassette. A FlashGel DNA marker was also loaded on the gel. Both WT and TLR9-/- bands have a length of approximately 340 bp. (TIF)

Figure S2 B6.TLR9-/- (OR) mice suffer from significantly more anemia than their B6.WT(Jv) counterparts during P. malariae infection. Between day 8 and day 16 pi, 10 μl of blood was taken from the tail vein and with the use of the “SDS-haemichrome method”, the concentration of hemoglobin was measured colorimetrically in B6.WT(Jv, black circles) and B6.TLR9-/- (OR, grey squares) mice. From each individual mouse, values of the lowest hemoglobin concentration after primary peak parasitemia are presented. The dashed line represents the hemoglobin level in naive mice, which is approximately 14 g/dl. The hemoglobin levels were restored to normal both in B6.WT(Jv) and B6.TLR9-/- (OR) mice around day 16 pi (data not shown). The horizontal lines indicate the group medians. Data are representative for 3 independent experiments with at least 5 mice per group for each experiment. The numbers of mice (n) in each group are depicted in the graph legend. **, \( p < 0.01 \); ***, \( p < 0.001 \).

Figure S3 Altered IgM and IgG subtype levels after P. malariae infection in B6.TLR9-/- (OR) vs. B6.WT(Jv) mice. B6.WT(Jv, black circles) and B6.TLR9-/- (OR, grey squares) mice were infected with 10^6 P. malariae PRCs and heparinized plasma samples were collected at 0, 21 and 42 days pi. The levels of IgM (A), IgG (B) and IgG subclasses IgG2c (C), IgG2b (D) and IgG1 (E) in naive and infected B6.WT(Jv) and B6.TLR9-/- (OR) were determined by ELISA and compared to a laboratory standard as detailed in the supporting Text S1. Horizontal lines indicate the group medians and each dot represents data from a single animal. Data are a compilation of two independent experiments with at least five mice per infected group at each time point. The numbers of mice (n) in each group are depicted in the graph legend. *, \( p < 0.05 \); **, \( p < 0.01 \); ***, \( p < 0.001 \).

Table S1 Background strain characterization via SNP markers. The genetic background of the mice was determined by analysis of 384 SNPs. The results for 4 B6.WT(Jv), 4 B6.TLR9-/- (OR), 3 B6.WT(BC) and 3 B6.TLR9-/- (BC) are compared with the profiles of one pure C57Bl/6 and one pure 129 mouse. The location of the TLR9 gene on chromosome 9 is shaded in grey. All loci that do not discriminate between C57Bl/6 and 129 are excluded (shaded in grey). Vs and Fs are the allele names (refers to VIC and FAM respectively). 1 = homozygous C57Bl/6; 0.5 = heterozygous for C57Bl/6 allele (green); 0 = homozygous for non C57Bl/6 allele (yellow). Percentage of C57Bl/6 DNA and average % C57Bl/6 DNA in each group is indicated at the bottom of the sheet. (DOC)

Acknowledgments

The authors thank Prof. Paul Proost and Prof. Adrian Liston for their constructive feedback and for critically reviewing the manuscript.

Author Contributions

Conceived and designed the experiments: NG EM SV GO PEVdS. Performed the experiments: NG EM SV NL GT BC SL HH PEVdS. Analyzed the data: NG EM SV GO PEVdS. Contributed reagents/materials/analysis tools: SM. Wrote the paper: NG GO PEVdS.

References

1. Thorsby E, Lie BA (2005) HLA associated genetic predisposition to autoimmune diseases: Genes involved and possible mechanisms. Transpl Immunol 14: 175–182.

2. Hafler DA, Compston A, Sawcer S, Landser ES, Daly MJ, et al. (2007) Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 357: 851–862.
3. Nejetsev S, Howson JM, Walker NM, Szezko J, Field SF, et al. (2007) Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 456: 887–892.

4. MacKay K, Eysy E, Myrcosogh A, Milicie A, Barton A, et al. (2002) Whole-genome linkage analysis of rheumatoid arthritis susceptibility loci in 252 affected sibling pairs in the United Kingdom. Arthritis Rheum 46: 632–639.

5. Lyke KE, Fernandez-Vina MA, Cao K, Hollenbach J, Coulibaly D, et al. (2011) Association of HLA alleles with Plasmodium falciparum severity in Malian children. Tissue Antigens 77: 562–571.

6. Jepson A, Snay-Joos F, Banya W, Hassan-King M, Froodan A, et al. (1997) Genetic linkage of mild malaria to the major histocompatibility complex in Gambian children: study of affected sibling pairs. BMJ 315: 96–97.

7. Huger JP, Chatellier M, Zosali H, Lsvgase S, Geardz JP, et al. (2001) Association of NOD2 leukocyte-rich repeat variants with susceptibility to Crohn’s disease. Nature 411: 599–603.

8. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, et al. (2010) Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s Disease susceptibility loci. Nat Genet 42: 1114–1125.

9. Schroder NW, Schumann RR (2005) Single-nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 5: 156–164.

10. Meckelhaus FP, Hamamaon L, von Gaertner C, Bcludo-Addo G, von Kelinsorgen G, et al. (2006) Common polymorphisms of toll-like receptors 4 and 9 are associated with the clinical manifestation of malaria during pregnancy. J Infect Dis 194: 184–188.

11. Franklin BS, Ishizaka ST, Lamphier M, Gusovsky F, Hansen H, et al. (2011) Therapeutic targeting of nucleic acid-sensing Toll-like receptors prevents experimental cerebral malaria. Proc Natl Acad Sci U S A 108: 6389–6394.

12. Orias S, Casrav S, Gomez A, Hoebbe C, Pantayamao N, Maalon Y, et al. (2010) Mechanisms of genetically-based tolerance to malaria. Gene 467: 1–12.

13. McClay MB, Netea MG, Hermens CC, Jansen T, Jacobs L, et al. (2007) Plasmodium falciparum infection causes proinflammatory priming of human Toll-like receptors. J Immunol 179: 162–171.

14. Franklin BS, Parorce P, Azade MA, Luiji F, Report C, et al. (2009) Malarial primes the innate immune response due to interleukin-gamma induced enhancement of toll-like receptor expression and function. Proc Natl Acad Sci U S A 106: 7979–7984.

15. Frankin BS, Ishizaka ST, Lamphier M, Gusovsky F, Hansen H, et al. (2011) The genetic susceptibility to Toll-like-receptor 4 and murine necrosis factor-alpha polymorphisms with Plasmodium falciparum blood infection levels. Infect Immun 80: 6086–6096.

16. Loza C, Saravia C, Gomez A, Hoebbe C, Pantayamao N, Maalon Y, et al. (2010) Cutting edge: the acquisition of TLR tolerance during malaria infection impacts T cell activation. J Immunol 184: 5923–5925.

17. Griffith JW, O’Connor C, Bernard K, Town T, Goldstein DR, et al. (2007) Toll-like receptor modulation of murine cerebral malaria is dependent on the genetic background of the host. J Infect Dis 196: 1533–1546.

18. Sigmond CJ (2000) Viewpoint: are studies in genetically altered mice out of context on background of the host. J Neuroimmunol 107: 217–223.

19. Langhorne J, Quin SJ, Sanni LA (2002) Mouse models of blood-stage malaria infections: immune responses and cytokines involved in protection and pathology. Chem Immunol 80: 204–228.

20. Taylor-Robinson AW, Phillips RS (1994) B cells are required for the switch from Th1- to Th2-regulated immune responses to Plasmodium chabaudi chabaudi infection. Infect Immun 62: 2490–2498.

21. Motto MM, Brown KN, Holder AA, Jarra W (1998) Acute Plasmodium chabaudi chabaudi malaria infection induces antibodies which bind to the surfaces of parasitized erythrocytes and promote their phagocytosis by macrophages in vitro. Infect Immun 66: 4080–4086.

22. Jagerlehner A, Maurer P, Bessa J, Hinton HJ, Kopf M, et al. (2007) TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol 179: 2415–2430.

23. Lin L, Gerth AJ, Peng SL (2004) CpG DNA redirects class-switching towards Th1-like Ig isotype production via TLR9 and MyD88. Eur J Immunol 34: 1403–1407.

24. Kwiatkowski D (2000) Genetic susceptibility to malaria getting complex. Curr Opin Genet Dev 10: 320–324.

25. Rihet P, Traore Y, Abel L, Aucan C, Traore-Leroux T, et al. (1998) Malaria in humans: Plasmodium falciparum blood infection levels are linked to chromosomal regions 1q31-q33. Infect Genet Evol 8: 385–392.

26. Beck JA, Lloyd S, Hafezparast M, Leonard-Pierce M, Epping JT, et al. (2000) Genealogies of mice inbred strains. Nat Genet 24: 23–25.

27. Stevenson MM, Lyanga JJ, Skamene E (1982) Murine malaria: genetic control of resistance to Plasmodium berghei. Infect Immun 38: 80–88.

28. Fortin A, Stevenson MM, Gros P (2002) Complex genetic control of susceptibility to malaria in mice. Genes Immun 3: 177–186.

29. Chang KH, Tam M, Stevenson MM (2004) Inappropriately low reticuloendotheliosis in severe malarial anemia correlates with suppression in the development of late erythrocyte precursors. Blood 103: 3727–3735.

30. Fortin A, Belouchi A, Tam MF, Cardon L, Skamene E, et al. (1997) Genetic control of blood parasitaemia in mouse malaria maps to chromosome 6. Nat Genet 17: 302–303.

31. Min-Oo G, Fortin A, Pitar A, Tam M, Stevenson MM, et al. (2007) Complex genetic control of susceptibility to malaria: polygenic control of the major histocompatibility complex. J Exp Med 204: 511–524.

32. Hernandez-Valladares M, Rihet P, o-Mo-Yosh OK, Iqra FA (2004) Mapping of a new quantitative trait locus for resistance to malaria in mice by a comparative mapping approach with human Chromosome 5q13-q33. Immunogenetics 56: 115–117.

33. Fooe SJ, Burt RA, Baldwin TM, Prenter A, Roberts AW, et al. (1997) Mouse loci for malaria-induced mortality and the control of parasitaemia. Nat Genet 17: 380–381.

34. Montague M (1999) Effect of the genetic background on the phenotype of mouse mutations. Annu Rev Neuro 11: 381–410.

35. Yoshi K, Moriwaki K (2006) Mouse phenotype research: implications of genetic context on phenotype. PLoS ONE 1: e20398.
59. Wolfer DP, Crusio WE, Lipp HP (2002) Knockout mice: simple solutions to the problems of genetic background and flanking genes. Trends Neurosci 25: 336–340.
60. Crusio WE (2004) Flanking gene and genetic background problems in genetically manipulated mice. Biol Psychiatry 56: 381–385.
61. Hu J, Van den Steen PE, Sang QX, Opdenakker G (2007) Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 6: 480–498.
62. Taft RA, Davisson M, Wiles MV (2006) Know thy mouse. Trends Genet 22: 649–653.
63. Stevens JC, Banks GT, Festing MF, Fisher EM (2007) Quiet mutations in inbred strains of mice. Trends Mol Med 13: 512–519.
64. Kiselycznyk C, Holmes A (2011) All (C57BL/6) Mice are not Created Equal. Front Neurosci 5: 10.
65. Bygrave AE, Rose KL, Cortes-Hernandez J, Warren J, Rigby RJ, et al. (2004) Spontaneous autoimmunity in 129 and C57BL/6 mice-implications for autoimmunity described in gene-targeted mice. PLoS Biol 2: E243.
66. Li C, Seixas E, Langhorne J (2001) Rodent malarias: the mouse as a model for understanding immune responses and pathology induced by the erythrocytic stages of the parasite. Med Microbiol Immunol 189: 115–126.
67. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, et al. (2009) Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139: 485–496.
68. Hisaeda H, Tetsutani K, Imai T, Moriya C, Tu L, et al. (2008) Malaria parasites require TLR9 signaling for immune evasion by activating regulatory T cells. J Immunol 180: 2496–2503.
69. Wunderlich F, Marinovski P, Benten WP, Schmit-Wrede HP, Mosmann H (1991) Testosterone and other gonadal factor(s) restrict the efficacy of genes controlling resistance to Plasmodium chabaudi chabaudi malaria. Parasite Immunol 13: 357–367.
70. Hemmi H, Takuchi O, Kawai T, Kaisho T, Sato S, et al. (2000) A Toll-like receptor recognizes bacterial DNA. Nature 406: 740–745.
71. Van den Steen PE, Geurts N, Deroost K, Van Aelst I, Verheyen S, et al. (2010) Immunopathology and dexamethasone therapy in a new model for malaria-associated acute respiratory distress syndrome. Am J Respir Crit Care Med 181: 957–968.
72. Akamori BD, Kazoi S, Suzuki M (1996) Recombinant mouse IGF-II boosts specific serum anti-plasmodial IgG subtype titres and suppresses parasitaemia in Plasmodium chabaudi chabaudi infection. Parasite Immunol 18: 193–199.
73. Sanni LA, Jarra W, Li C, Langhorne J (2004) Cerebral edema and cerebral hemorrhages in interleukin-10-deficient mice infected with Plasmodium chabaudi. Infect Immun 72: 3054–3058.
74. Meding SJ, Cheng SC, Simon-Haarhaus B, Langhorne J (1990) Role of gamma interferon during infection with Plasmodium chabaudi chabaudi. Infect Immun 58: 3671–3678.
75. The Jackson Laboratory (2007) Breeding strategies forMaintaining Colonies of Laboratory Mice. Available: http://iacuc.ucsd.edu/PDF_References/ BreedingStrategiesManual.pdf. Accessed 2011 April 17.
76. CLEA Japan (2011) Japan mouse/rat strain resources database. Available: http://www.shigen.nig.ac.jp/mouse/jmsr/top.jsp. Accessed 2011 April 17.
77. Yoshida S, Araki H, Yokomine T (2010) Baculovirus-based nasal drop vaccine confers complete protection against malaria by natural boosting of vaccine-induced antibodies in mice. Infect Immun 78: 595–602.
78. Griffith JW, Sun T, McIntosh MT, Rocaia R (2009) Pure Hemoozin is inflammatory in vivo and activates the NALP3 inflammasome via release of uric acid. J Immunol 183: 5208–5220.
79. Wu X, Gowda NM, Kumar S, Gowda DC (2010) Protein-DNA complex is the exclusive malaria parasite component that activates dendritic cells and triggers innate immune responses. J Immunol 184: 4338–4348.
80. Yasuda K, Yu P, Kirschning CJ, Schlatter B, Schmitz F, et al. (2005) Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways. J Immunol 174: 6129–6136.